• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种基于血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)和糖类抗原72-4(CA72-4)水平筛查胃癌的替代方法。

An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4.

作者信息

Yu Junxiu, Zheng Wanlei

机构信息

Department of Gastrointestinal Surgery, Liaocheng People's Hospital and Liaocheng Clinical School of Taishan Medical University, Liaocheng, People's Republic of China.

Department of Gastrointestinal Surgery, Liaocheng People's Hospital, 67 Dongchang West Road, Dongchangfu District, Liaocheng, Shandong Province, 252000, People's Republic of China.

出版信息

J Gastrointest Cancer. 2018 Mar;49(1):57-62. doi: 10.1007/s12029-016-9912-7.

DOI:10.1007/s12029-016-9912-7
PMID:28028765
Abstract

PURPOSE

The goal of this study was to create a novel method for screening gastric cancer (GC) based on serum levels of carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), and cancer antigen 72-4 (CA72-4) tumor markers.

METHODS

Retrospectively, the predictive value for GC was calculated using a logistic analysis on serum levels of CEA, CA19-9, and CA72-4 from 216 GC and 49 benign patients. The predictive value was used to make a recommendation system on whether further GC screening was necessary. Prospectively, 80 GC and 33 benign patients were used to assess the value of this method.

RESULTS

The recommendation system to determine whether additional GC screening was necessary consisted of three grades: grade I, no proposals; grade II, proposals; grade III, strong proposals. Additional screening was suggested when the predictive value was ≤0.700 (grade I), 0.700-0.850 (grade II), and >0.850 (grade III). Of the total 216 GC patients, 20.4, 27.8, and 51.9% were classified as grades I, II, and III, respectively. Of the 49 benign cases, 57.1, 32.7, and 10.2% were classified as grades I, II, and III, respectively. Of the 80 prospective GC patients, 17.3, 28.4, and 54.3% were classified as grades I, II, and III, respectively. Of the 33 prospective benign cases, 54.6, 33.3, and 12.1% were classified as grades I, II, and III, respectively.

CONCLUSION

The new screening recommendation system based on serum levels of CEA, CA19-9, and CA72-4 is an effective approach for detecting GC.

摘要

目的

本研究的目标是创建一种基于癌胚抗原(CEA)、癌抗原19-9(CA19-9)和癌抗原72-4(CA72-4)肿瘤标志物血清水平的新型胃癌(GC)筛查方法。

方法

回顾性地对216例胃癌患者和49例良性疾病患者的CEA、CA19-9和CA72-4血清水平进行逻辑分析,计算其对胃癌的预测价值。该预测价值用于建立一个关于是否需要进一步进行胃癌筛查的推荐系统。前瞻性地选取80例胃癌患者和33例良性疾病患者来评估该方法的价值。

结果

判断是否需要额外进行胃癌筛查的推荐系统分为三个等级:一级,无建议;二级,建议;三级,强烈建议。当预测价值≤0.700(一级)、0.700 - 0.850(二级)和>0.850(三级)时,建议进行额外筛查。在总共216例胃癌患者中,分别有20.4%、27.8%和51.9%被归类为一级、二级和三级。在49例良性病例中,分别有57.1%、32.7%和10.2%被归类为一级、二级和三级。在80例前瞻性胃癌患者中,分别有17.3%、28.4%和54.3%被归类为一级、二级和三级。在33例前瞻性良性病例中,分别有54.6%、33.3%和12.1%被归类为一级、二级和三级。

结论

基于CEA、CA19-9和CA72-4血清水平的新型筛查推荐系统是检测胃癌的有效方法。

相似文献

1
An Alternative Method for Screening Gastric Cancer Based on Serum Levels of CEA, CA19-9, and CA72-4.一种基于血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)和糖类抗原72-4(CA72-4)水平筛查胃癌的替代方法。
J Gastrointest Cancer. 2018 Mar;49(1):57-62. doi: 10.1007/s12029-016-9912-7.
2
CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.CA72-4联合癌胚抗原(CEA)、糖类抗原125(CA125)和糖类抗原19-9(CA19-9)可提高胃癌早期诊断的敏感性。
Clin Chim Acta. 2014 Nov 1;437:183-6. doi: 10.1016/j.cca.2014.07.034. Epub 2014 Jul 30.
3
Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.胃癌患者肿瘤标志物的临床评估与预后评价。
Int J Biol Markers. 2013 Jun 28;28(2):192-200. doi: 10.5301/jbm.5000023.
4
Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.血清癌胚抗原、糖类抗原19-9及糖类抗原72-4在胃癌患者中的临床意义及诊断价值
Oncotarget. 2016 Aug 2;7(31):49565-49573. doi: 10.18632/oncotarget.10391.
5
Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.血清癌胚抗原、糖类抗原72-4、糖类抗原19-9及肿瘤特异性生长因子联合检测在胃癌诊断中的价值
Asian Pac J Cancer Prev. 2015;16(9):3867-70. doi: 10.7314/apjcp.2015.16.9.3867.
6
Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer.血清癌胚抗原、糖类抗原72-4、糖类抗原19-9、糖类抗原15-3和糖类抗原12-5联合检测在胃癌诊断中的价值
Ann Clin Lab Sci. 2017 May;47(3):260-263.
7
The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.癌胚抗原、CA19.9和CA72.4的血清及胃液水平在胃癌患者中的作用
J Cancer Res Clin Oncol. 1998;124(8):450-5. doi: 10.1007/s004320050198.
8
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.胃癌患者中CA72-4与CEA和CA19-9相比的临床意义及预后价值
Dis Markers. 2000;16(3-4):105-10. doi: 10.1155/2000/595492.
9
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.CEA、CA19-9、CA72-4和CA125在接受新辅助化疗的胃癌患者中的临床评估
World J Surg Oncol. 2014 Dec 29;12:397. doi: 10.1186/1477-7819-12-397.
10
[Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].血清癌胚抗原、糖类抗原19-9、糖类抗原72-4及糖类抗原242在胃癌诊断及预后中的临床价值
Zhonghua Wei Chang Wai Ke Za Zhi. 2012 Feb;15(2):161-4.

引用本文的文献

1
Identification and potential mechanism of a novel gastric cancer suppressor tRF-24-6VR8K09LE9.一种新型胃癌抑制因子tRF-24-6VR8K09LE9的鉴定及潜在机制
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 24. doi: 10.1007/s00210-025-03914-5.
2
Serum LINC01133 combined with CEA and CA19-9 contributes to the diagnosis and survival prognosis of gastric cancer.血清 LINC01133 联合 CEA 和 CA19-9 有助于胃癌的诊断和生存预后评估。
Medicine (Baltimore). 2024 Nov 15;103(46):e40564. doi: 10.1097/MD.0000000000040564.
3
Deciphering the Landscape of GATA-Mediated Transcriptional Regulation in Gastric Cancer.

本文引用的文献

1
Screening in GI Cancers: The Role of Genetics.胃肠道癌症的筛查:遗传学的作用。
J Clin Oncol. 2015 Jun 1;33(16):1721-8. doi: 10.1200/JCO.2014.60.6764. Epub 2015 Apr 27.
2
Impact of endoscopic screening on mortality reduction from gastric cancer.内镜筛查对降低胃癌死亡率的影响。
World J Gastroenterol. 2015 Feb 28;21(8):2460-6. doi: 10.3748/wjg.v21.i8.2460.
3
Gastric cancer screening uptake trends in Korea: results for the National Cancer Screening Program from 2002 to 2011: a prospective cross-sectional study.韩国胃癌筛查的接受趋势:2002年至2011年国家癌症筛查计划的结果:一项前瞻性横断面研究。
解析胃癌中GATA介导的转录调控格局
Antioxidants (Basel). 2024 Oct 18;13(10):1267. doi: 10.3390/antiox13101267.
4
Gastric Cancer: An Up-to-Date Review with New Insights into Early-Onset Gastric Cancer.胃癌:对早期胃癌新见解的最新综述
Cancers (Basel). 2024 Sep 15;16(18):3163. doi: 10.3390/cancers16183163.
5
CCL21 and CLDN11 Are Key Driving Factors of Lymph Node Metastasis in Gastric Cancer.CCL21 和 CLDN11 是胃癌淋巴结转移的关键驱动因素。
Cancer Control. 2024 Jan-Dec;31:10732748241238616. doi: 10.1177/10732748241238616.
6
The ASH1L-AS1-ASH1L axis controls NME1-mediated activation of the RAS signaling in gastric cancer.ASH1L-AS1-ASH1L 轴控制 NME1 介导的胃癌中 RAS 信号的激活。
Oncogene. 2023 Nov;42(46):3435-3445. doi: 10.1038/s41388-023-02855-8. Epub 2023 Oct 7.
7
Novel prognostic indicator combining inflammatory indicators and tumor markers for gastric cancer.新型联合炎症指标和肿瘤标志物的胃癌预后指标。
World J Surg Oncol. 2023 Feb 18;21(1):50. doi: 10.1186/s12957-023-02926-w.
8
Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy.新型药物递送系统作为胃癌治疗的新兴平台
Pharmaceutics. 2022 Jul 29;14(8):1576. doi: 10.3390/pharmaceutics14081576.
9
Diagnostic value of combined detection of CA72-4, CA19-9, and carcinoembryonic antigen comparing to CA72-4 alone in gastric cancer: a systematic review and meta-analysis.CA72-4、CA19-9和癌胚抗原联合检测与单独检测CA72-4在胃癌诊断中的价值:一项系统评价和Meta分析
Transl Cancer Res. 2022 Apr;11(4):848-856. doi: 10.21037/tcr-22-537.
10
Differential Long Non-Coding RNA Expression Analysis in Chronic Non-Atrophic Gastritis, Gastric Mucosal Intraepithelial Neoplasia, and Gastric Cancer Tissues.慢性非萎缩性胃炎、胃黏膜上皮内瘤变及胃癌组织中差异长链非编码RNA表达分析
Front Genet. 2022 Apr 27;13:833857. doi: 10.3389/fgene.2022.833857. eCollection 2022.
Medicine (Baltimore). 2015 Feb;94(8):e533. doi: 10.1097/MD.0000000000000533.
4
The new modified ABCD method for gastric neoplasm screening.用于胃癌筛查的新型改良ABCD方法。
Gastric Cancer. 2016 Jan;19(1):128-35. doi: 10.1007/s10120-015-0473-4. Epub 2015 Feb 8.
5
Familial gastric cancer: genetic susceptibility, pathology, and implications for management.家族性胃癌:遗传易感性、病理学及对治疗的影响。
Lancet Oncol. 2015 Feb;16(2):e60-70. doi: 10.1016/S1470-2045(14)71016-2.
6
Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening.美国 2015 年癌症筛查:对当前美国癌症协会指南和癌症筛查中当前问题的回顾。
CA Cancer J Clin. 2015 Jan-Feb;65(1):30-54. doi: 10.3322/caac.21261. Epub 2015 Jan 8.
7
Cancer statistics, 2015.癌症统计数据,2015 年。
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.
8
Implementation of gastric cancer screening - the global experience.胃癌筛查的实施——全球经验
Best Pract Res Clin Gastroenterol. 2014 Dec;28(6):1093-106. doi: 10.1016/j.bpg.2014.09.005. Epub 2014 Sep 28.
9
Identification of prognostic factors and surgical indications for metastatic gastric cancer.转移性胃癌预后因素及手术指征的识别
BMC Cancer. 2014 Jun 6;14:409. doi: 10.1186/1471-2407-14-409.
10
Prognostic value of preoperative serum tumor markers in gastric cancer.术前血清肿瘤标志物在胃癌中的预后价值
World J Clin Oncol. 2014 May 10;5(2):170-6. doi: 10.5306/wjco.v5.i2.170.